Astria Tangible Book Value Per Share from 2010 to 2024
| ATXS Stock | USD 9.54 0.11 1.17% |
Tangible Book Value Per Share | First Reported 2010-12-31 | Previous Quarter 8.07069182 | Current Value 8.47 | Quarterly Volatility 242.04291967 |
Check Astria Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Astria main balance sheet or income statement drivers, such as Selling General Administrative of 12.7 M, Other Operating Expenses of 37.7 M or Research Development of 25 M, as well as many exotic indicators such as Price To Sales Ratio of 51.69, Dividend Yield of 0.0 or PTB Ratio of 0.59. Astria financial statements analysis is a perfect complement when working with Astria Therapeutics Valuation or Volatility modules.
Astria | Tangible Book Value Per Share |
Latest Astria Therapeutics' Tangible Book Value Per Share Growth Pattern
Below is the plot of the Tangible Book Value Per Share of Astria Therapeutics over the last few years. It is Astria Therapeutics' Tangible Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Astria Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Tangible Book Value Per Share | 10 Years Trend |
|
Tangible Book Value Per Share |
| Timeline |
Astria Tangible Book Value Per Share Regression Statistics
| Arithmetic Mean | (87.67) | |
| Coefficient Of Variation | (276.10) | |
| Mean Deviation | 201.71 | |
| Median | 13.30 | |
| Standard Deviation | 242.04 | |
| Sample Variance | 58,585 | |
| Range | 883 | |
| R-Value | 0.59 | |
| Mean Square Error | 41,018 | |
| R-Squared | 0.35 | |
| Significance | 0.02 | |
| Slope | 32.01 | |
| Total Sum of Squares | 820,187 |
Astria Tangible Book Value Per Share History
About Astria Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Astria Therapeutics income statement, its balance sheet, and the statement of cash flows. Astria Therapeutics investors use historical funamental indicators, such as Astria Therapeutics's Tangible Book Value Per Share, to determine how well the company is positioned to perform in the future. Although Astria Therapeutics investors may use each financial statement separately, they are all related. The changes in Astria Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Astria Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Astria Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Astria Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Tangible Book Value Per Share | 8.07 | 8.47 |
Pair Trading with Astria Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Astria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Astria Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Astria Stock
| 0.89 | VRDN | Viridian Therapeutics | PairCorr |
| 0.89 | EFTR | Effector Therapeutics | PairCorr |
Moving against Astria Stock
| 0.74 | DSGN | Design Therapeutics | PairCorr |
| 0.71 | ELYM | Eliem Therapeutics | PairCorr |
| 0.63 | ELVN | Enliven Therapeutics | PairCorr |
| 0.63 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
The ability to find closely correlated positions to Astria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Astria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Astria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Astria Therapeutics to buy it.
The correlation of Astria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Astria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Astria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Astria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Astria Therapeutics Correlation against competitors. For more information on how to buy Astria Stock please use our How to Invest in Astria Therapeutics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Complementary Tools for Astria Stock analysis
When running Astria Therapeutics' price analysis, check to measure Astria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Astria Therapeutics is operating at the current time. Most of Astria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Astria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Astria Therapeutics' price. Additionally, you may evaluate how the addition of Astria Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |
Is Astria Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Astria Therapeutics. If investors know Astria will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Astria Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.40) | Return On Assets (0.16) | Return On Equity (0.28) |
The market value of Astria Therapeutics is measured differently than its book value, which is the value of Astria that is recorded on the company's balance sheet. Investors also form their own opinion of Astria Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Astria Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Astria Therapeutics' market value can be influenced by many factors that don't directly affect Astria Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Astria Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Astria Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Astria Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.